VALBONNE, FRANCE -- TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and/or meet investors at a number of leading forthcoming investor conferences.
Technology news on Global TechWire, reporting the business of life sciences and innovation. Published by Innovative Public Relations, Inc., a Research Triangle, North Carolina-based publicity and branding consultancy. Learn more @ www.innovativepublicrelations.com.
These investor conferences include:
15th Annual Biotech in Europe Forum, organized by Sachs Associates, Basel, Switzerland - September 29 – 30, 2015
Société Générale Healthcare & Biotechnology Conference, Paris, France - November 5, 2015
3rd Annual EU Advanced Therapies Investor Day organized by the Alliance for Regenerative Medicine, London, UK – November 12, 2015
3rd European Healthcare Conference organized by Bryan Garnier, Paris, France - November 12 – 13, 2015
Salon Actionaria, Paris, France - November 20 – 21, 2015
The 19th Oddo forum, organized by Oddo, Lyon, France - January 7 – 8, 2016
JP Morgan 34th Annual Healthcare Conference, San Francisco, US - January 11 – 15, 2016
NobleCon12, the 12th Annual Emerging Growth Investor Conference, organized by Noble Financial Capital Markets, Florida, US - January 19 – 20, 2016.
About TxCell: www.txcell.com
TxCell develops innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave(R) in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. Listed on the regulated market Euronext Paris, TxCell is a spin-off of Inserm (France’s National Institute for Health and Medical Research). TxCell has 66 employees based both at the headquarters located in the Sophia Antipolis technology park, Nice, France and at its manufacturing site in Besançon.
